Oct 14, 2020
When the World Ovarian Cancer Coalition launched The Every Woman Study™ in 2018 we closed a significant gap in the understanding of the experiences of women living with ovarian cancer. With more than 1,500 women from 44 countries contributing to the research, the study remains the largest review of ovarian cancer from the point of view of those living with the disease.
The study identified many issues including how the lack of awareness on both the part of women and clinicians can lead to unnecessary delays in diagnosis. It also showed that there are significant variations between countries on all fronts with regards to access to specialist treatment, including genetic testing and crucial clinical trials.
Because of this, many women are missing out on treatments that have the potential to improve survival and quality of life. The study also found significant shortfalls between what women need and what they receive in terms of information, as well as emotional and practical support.
The Global Ovarian Cancer Charter is an important next step for the Coalition. With six key global goals, the charter is a rallying cry for anyone with an interest in improving survival and quality of life for every woman diagnosed with ovarian cancer.
The six global goals are:
We genuinely believe that by showcasing the enormous commitment within the global ovarian cancer community, at all levels, we will be more powerful together.
Meeting charter goals requires both individuals and organizations to help drive forward meaningful conversations that lead to actions. We are fortunate to have several what we call “Charter Champions” – those organizations whose innovations will help lead the way for change.
In this spirit of innovation, we are delighted to be working with Teckro as our newest industry partner. Within our global goals, clinical trials play an important role in advancing new ovarian cancer treatments. Making clinical trials as available and accessible to as many women as possible is paramount. Teckro’s own commitment to make clinical trials more simple, accessible and transparent aligns very well with our Coalition priorities.
We are very excited to be collaborating with Teckro!
To encourage conversation that will help bring our charter to life, we are launching our Charter Summit Series. These virtual events will look at what we can do to progress against the charter goals by bringing together key stakeholders, including women with ovarian cancer, patient advocacy groups, clinicians, researchers, policymakers, and the industry.
The first event, Making Ovarian Cancer a Global Priority, is next Thursday, October 22. We will share our 2020 World Ovarian Cancer Coalition Atlas, which sets out updated global data on incidence, mortality, and survival. Our expert global panel will discuss challenges and ideas on how to tackle the inequalities that this atlas brings to light.
There are a number of ways you can get involved. For example:
The Global Ovarian Cancer Charter belongs to all of us who wish to change the future of ovarian cancer for all women – no matter who they are or where they live.
We are more #PowerfulTogether!
CEO of the World Ovarian Cancer Coalition, Clara MacKay has nearly 20 years of experience in cancer advocacy, including senior-level positions in UK organizations covering ovarian, pancreatic, bowel, prostate and breast cancer. Clara was a founding member of the World Pancreatic Cancer Coalition and Chair of Cancer 52 – a network of nearly 100 cancer groups representing the interests of rare and less common cancers. In 2015 she was appointed to an Independent Cancer Taskforce established by NHS England to develop a five-year strategy for cancer services. After 25 years in the UK, Clara returned to her native Nova Scotia, Canada in 2016. Clara was recently appointed Chair of the national Canadian charity Craig’s Cause Pancreatic Cancer Society.
You can connect with Clara on LinkedIn.
The World Ovarian Cancer Coalition is a global not-for-profit that works to ensure that every woman diagnosed with ovarian cancer has the best chance of survival and the best quality of life possible. The Coalition works with a network of more than 160 patient advocacy partner organizations across 47 countries.